| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Patterns of recurrence after surgery alone versus preoperative chemoradiotherapy and surgery in the CROSS trials.
|
J Clin Oncol
|
2014
|
4.59
|
|
2
|
Cure of Barrett's carcinoma by ifosfamide chemotherapy.
|
Eur J Gastroenterol Hepatol
|
2002
|
1.92
|
|
3
|
Ultrasound, computed tomography, or the combination for the detection of supraclavicular lymph nodes in patients with esophageal or gastric cardia cancer: a comparative study.
|
J Surg Oncol
|
2007
|
1.42
|
|
4
|
Highlights of the EORTC St. Gallen International Expert Consensus on the primary therapy of gastric, gastroesophageal and oesophageal cancer - differential treatment strategies for subtypes of early gastroesophageal cancer.
|
Eur J Cancer
|
2012
|
1.32
|
|
5
|
Chemotherapy followed by surgery versus surgery alone in patients with resectable oesophageal squamous cell carcinoma: long-term results of a randomized controlled trial.
|
BMC Cancer
|
2011
|
1.27
|
|
6
|
The potential of statins as part of anti-cancer treatment.
|
Eur J Cancer
|
2005
|
1.07
|
|
7
|
Prophylaxis of irinotecan-induced diarrhea with neomycin and potential role for UGT1A1*28 genotype screening: a double-blind, randomized, placebo-controlled study.
|
Oncologist
|
2006
|
1.03
|
|
8
|
Adjuvant intra-arterial chemotherapy and radiotherapy versus surgery alone in resectable pancreatic and periampullary cancer: a prospective randomized controlled trial.
|
Ann Surg
|
2008
|
0.98
|
|
9
|
Phase I safety, pharmacokinetic, and pharmacodynamic study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 in patients with advanced cancer.
|
J Clin Oncol
|
2005
|
0.96
|
|
10
|
Lymph node retrieval during esophagectomy with and without neoadjuvant chemoradiotherapy: prognostic and therapeutic impact on survival.
|
Ann Surg
|
2014
|
0.95
|
|
11
|
Phase I and pharmacologic study of PKI166, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies.
|
Clin Cancer Res
|
2005
|
0.93
|
|
12
|
Fluorodeoxyglucose positron emission tomography for evaluating early response during neoadjuvant chemoradiotherapy in patients with potentially curable esophageal cancer.
|
Ann Surg
|
2011
|
0.93
|
|
13
|
A comparison between low-volume referring regional centers and a high-volume referral center in quality of preoperative metastasis detection in esophageal carcinoma.
|
Am J Gastroenterol
|
2006
|
0.92
|
|
14
|
WITHDRAWN: Chemotherapy for metastatic carcinoma of the esophagus and gastro-esophageal junction.
|
Cochrane Database Syst Rev
|
2010
|
0.89
|
|
15
|
Impact of a multidisciplinary tumour board meeting for upper-GI malignancies on clinical decision making: a prospective cohort study.
|
Int J Clin Oncol
|
2011
|
0.89
|
|
16
|
Randomized clinical trial of adenosine 5'-triphosphate on tumor growth and survival in advanced lung cancer patients.
|
Anticancer Drugs
|
2003
|
0.88
|
|
17
|
A phase I and pharmacokinetic study of weekly paclitaxel and carboplatin in patients with metastatic esophageal cancer.
|
Clin Cancer Res
|
2004
|
0.88
|
|
18
|
Neoadjuvant chemoradiotherapy for esophageal cancer: a review of meta-analyses.
|
World J Surg
|
2009
|
0.87
|
|
19
|
Phase I and pharmacokinetic study of the dolastatin 10 analogue TZT-1027, given on days 1 and 8 of a 3-week cycle in patients with advanced solid tumors.
|
Clin Cancer Res
|
2005
|
0.84
|
|
20
|
Quality of life during neoadjuvant treatment and after surgery for resectable esophageal carcinoma.
|
Int J Radiat Oncol Biol Phys
|
2007
|
0.83
|
|
21
|
Systemic treatment for oesophageal cancer.
|
Eur J Cancer
|
2005
|
0.81
|
|
22
|
NEOadjuvant therapy monitoring with PET and CT in Esophageal Cancer (NEOPEC-trial).
|
BMC Med Phys
|
2008
|
0.81
|
|
23
|
Phase II trial of Uracil/Tegafur plus leucovorin and celecoxib combined with radiotherapy in locally advanced pancreatic cancer.
|
Radiother Oncol
|
2010
|
0.80
|
|
24
|
Prolonged time to surgery after neoadjuvant chemoradiotherapy increases histopathological response without affecting survival in patients with esophageal or junctional cancer.
|
Ann Surg
|
2014
|
0.79
|
|
25
|
Continuous ambulatory peritoneal dialysis: pharmacokinetics and clinical outcome of paclitaxel and carboplatin treatment.
|
Cancer Chemother Pharmacol
|
2008
|
0.78
|
|
26
|
A phase I and pharmacologic study of the matrix metalloproteinase inhibitor CP-471,358 in patients with advanced solid tumors.
|
Cancer Chemother Pharmacol
|
2004
|
0.77
|
|
27
|
P53 and SOX2 Protein Expression Predicts Esophageal Adenocarcinoma in Response to Neoadjuvant Chemoradiotherapy.
|
Ann Surg
|
2017
|
0.76
|
|
28
|
[A man with an ulcerating swelling on the throat].
|
Ned Tijdschr Geneeskd
|
2014
|
0.75
|
|
29
|
Problems and needs in patients with incurable esophageal and pancreaticobiliary cancer: a descriptive study.
|
Gastroenterol Nurs
|
2015
|
0.75
|
|
30
|
Palliative chemotherapy and targeted therapies for esophageal and gastroesophageal junction cancer.
|
Cochrane Database Syst Rev
|
2017
|
0.75
|
|
31
|
P53 and SOX2 Protein Expression Predicts Esophageal Adenocarcinoma in Response to Neoadjuvant Chemoradiotherapy.
|
Ann Surg
|
2016
|
0.75
|
|
32
|
Impact of Surgical Approach on Long-term Survival in Esophageal Adenocarcinoma Patients With or Without Neoadjuvant Chemoradiotherapy.
|
Ann Surg
|
2017
|
0.75
|